Tirzepatide: What the Research Says
A dual GIP and GLP-1 receptor agonist — the first of its class. Newer than semaglutide, with a short but fast-growing body of head-to-head randomized trials.
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It's the first of a new pharmacological class — sometimes described as a “twincretin” because it engages two incretin hormone pathways in a single molecule.
Developed by Eli Lilly, tirzepatide was approved by the FDA in May 2022 under the brand name Mounjaro for type 2 diabetes, and in November 2023 under the brand name Zepbound for chronic weight management.
Compounded tirzepatide uses the same active ingredient but is prepared by licensed U.S. compounding pharmacies outside the FDA-approved brand pathway, under the 503A or 503B compounding framework. It is not FDA-approved; it is legally prepared under a separate regulatory framework.
How it works (mechanism of action)
GIP + GLP-1 activation
Tirzepatide binds both GIP and GLP-1 receptors, which are co-expressed in the pancreas, adipose tissue, and central nervous system. Preclinical receptor pharmacology (Willard et al., JCI Insight, 2020) showed tirzepatide acts as an imbalanced dual agonist — engaging the GIP receptor more strongly than the GLP-1 receptor, with biased GLP-1 signaling that favors cAMP generation over β-arrestin recruitment. Clinical efficacy comparisons are covered by the SURMOUNT and SURPASS programs below.
Reduced caloric intake
Central GLP-1 receptor activation reduces hunger and food-seeking behavior. GIP's role in appetite is less fully understood, but preclinical work suggests additive effects on body-weight regulation when combined with GLP-1 agonism rather than opposing it as older single-receptor GIP studies had suggested.
Insulin sensitivity in fat tissue
GIP receptors are highly expressed on adipocytes. Preclinical studies suggest tirzepatide may improve insulin sensitivity in adipose tissue and support more favorable body composition changes than GLP-1-only agents — though clinical body-composition data are still accumulating.
Glucose-dependent insulin release
Like GLP-1 agonists, tirzepatide stimulates insulin only when glucose is elevated and suppresses glucagon, so the hypoglycemia risk in non-diabetic users is low. SURPASS trials showed substantial HbA1c reductions in type 2 diabetes.
What the research suggests
Tirzepatide has the advantage of being studied against an already-best-in-class comparator (semaglutide) in head-to-head randomized trials. The SURMOUNT program targets obesity; the SURPASS program targets type 2 diabetes.
Weight management (SURMOUNT-1)
SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) was a 72-week, placebo-controlled trial of 2,539 adults with obesity but without diabetes. Participants on 15 mg tirzepatide lost a mean of 20.9% of body weight, compared with 3.1% on placebo. This is the largest mean weight loss reported in a modern pharmacotherapy trial for obesity.
Head-to-head vs. semaglutide (SURPASS-2)
SURPASS-2 (Frías et al., New England Journal of Medicine, 2021) directly compared tirzepatide with semaglutide in 1,879 patients with type 2 diabetes over 40 weeks. Tirzepatide at 15 mg produced greater HbA1c reduction and greater weight loss than semaglutide at 1 mg — though the dose comparison is imperfect since semaglutide's weight-management dose is 2.4 mg, not 1 mg.
Weight maintenance (SURMOUNT-4)
SURMOUNT-4 (Aronne et al., JAMA, 2024) studied what happens after 36 weeks of tirzepatide: participants randomized to continued tirzepatide maintained a mean additional 5.5% weight loss through week 88, while those switched to placebo regained roughly 14 percentage points of their earlier loss. The trial underscores that weight response is treatment- dependent, not a one-time effect.
What research has not settled
Long-term cardiovascular outcome data are still emerging; the SURPASS-CVOT trial is ongoing. Comparative data against the full 2.4 mg semaglutide dose are not yet mature. Compounded tirzepatide specifically has not been studied in dedicated randomized trials — clinical inferences rely on the brand-name data and shared active ingredient.
Administration
Tirzepatide is administered by weekly subcutaneous injection into the abdomen, thigh, or upper arm. In SURMOUNT and SURPASS trials, the dose was titrated upward from 2.5 mg weekly every four weeks, reaching therapeutic ranges of 5–15 mg. Slow titration reduces GI side effects during initiation.
Brand Zepbound is dosed 5–15 mg weekly for weight management; Mounjaro uses a similar range for type 2 diabetes. Compounded protocols are set by the prescribing clinician based on tolerability, goals, and response.
This is research and regulatory context, not prescribing guidance. Your clinician will determine dosing and titration based on your specific health profile.
Side effects & safety considerations
Tirzepatide's side-effect profile closely resembles that of GLP-1 agonists. Event rates in the SURMOUNT and SURPASS programs are well-documented.
Common side effects
Gastrointestinal effects dominate: nausea, diarrhea, vomiting, constipation, and decreased appetite. In SURMOUNT-1, about 78% of patients on the 15 mg dose reported GI symptoms versus 45% on placebo. Most resolve within the first several weeks; slow titration is the primary mitigation.
Serious but uncommon risks
Acute pancreatitis has been reported; post-marketing surveillance continues. Gallbladder-related events were elevated in trials. Tirzepatide carries the same FDA-labeled warning as GLP-1 agonists for medullary thyroid carcinoma based on rodent data; no confirmed causal signal in humans.
Contraindications
- •Personal or family history of medullary thyroid carcinoma
- •Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- •Pregnancy or breastfeeding
- •History of pancreatitis (relative contraindication)
- •Type 1 diabetes (tirzepatide is not a substitute for insulin)
Your prescribing clinician will review your medical history, medications, and goals before determining whether tirzepatide is appropriate. This page is educational, not medical advice.
Brand vs. compounded: regulatory context
Brand-name tirzepatide (Mounjaro, Zepbound) is FDA-approved for specific indications. Compounded tirzepatide is not FDA-approved — it is prepared on a patient-specific basis by licensed U.S. compounding pharmacies under the federal 503A and 503B frameworks.
Tirzepatide has at times appeared on the FDA drug shortage list, which is the regulatory condition that allows compounding pharmacies to prepare it for patients who cannot access brand-name supply. Shortage status is dynamic and is monitored by your clinician and pharmacy.
Compounded medications are prepared to the clinician's specifications and quality-tested before shipping, but they have not undergone the full FDA approval process that brand-name versions have. Patients considering compounded tirzepatide should understand this distinction.
Ready to see if tirzepatide is right for you?
Take a 3-minute assessment. A licensed clinician reviews your health history and goals, then prescribes only if tirzepatide is clinically appropriate. Shipped from licensed U.S. compounding pharmacies.
Deep dives on Tirzepatide
Research-backed articles covering specific topics in depth.